The Perrigo Company has received approval from the US FDA to manufacture and market prescription Naproxen Tablets USP, 250 mg, 375 mg and 500 mg.
The product is the AB-rated equivalent to Roche's Naprosyn Tablets, indicated for the treatment of arthritis, tendonitis, bursitis and for the relief of mild to moderate pain. Sales for the brand and generics were approximately $100 million in 2004.
Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand and contract manufacturing markets, a company release said.